Our portfolio company ReCatalyst reaches significant product milestones and signs a memorandum of understanding with a Membrane Electrode Assembly producer.
OCCIDENT participates in the € 17.9 million Series B funding round of Lausanne-based Lymphatica Medtech that develops novel treatment options for patients …
On the occasion of World Sepsis Day on September 13, we want to raise awareness about sepsis, a life-threatening condition that impacts millions globally each year.
We provide an exceptional opportunity for students at the Technical University of Munich to gain hands-on experience in venture capital while earning credits towards their Master's programs.
Tubulis' TUB-040, an ADC for platinum-resistant ovarian cancer, receives FDA Fast Track, expediting its development in Phase I/IIa trials to address urgent cancer treatment needs.
The OCCIDENT Team regularly improves its soft skills to enhance collaboration both internally and externally. In addition to our professional skills, we attach great importance to teamwork.